- Home
- IMPP vs CRDL Comparison
IMPP vs CRDL Comparison
Compare IMPP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- CRDL
- Stock Information
- Founded
- IMPP 1981
- CRDL 2017
- Country
- IMPP Greece
- CRDL Canada
- Employees
- IMPP N/A
- CRDL N/A
- Industry
- IMPP Marine Transportation
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- CRDL Health Care
- Exchange
- IMPP Nasdaq
- CRDL Nasdaq
- Market Cap
- IMPP 99.2M
- CRDL 102.0M
- IPO Year
- IMPP N/A
- CRDL N/A
- Fundamental
- Price
- IMPP $2.61
- CRDL $1.08
- Analyst Decision
- IMPP
- CRDL Strong Buy
- Analyst Count
- IMPP 0
- CRDL 3
- Target Price
- IMPP N/A
- CRDL $9.00
- AVG Volume (30 Days)
- IMPP 163.0K
- CRDL 223.0K
- Earning Date
- IMPP 05-15-2025
- CRDL 05-13-2025
- Dividend Yield
- IMPP N/A
- CRDL N/A
- EPS Growth
- IMPP N/A
- CRDL N/A
- EPS
- IMPP 1.40
- CRDL N/A
- Revenue
- IMPP $147,479,980.00
- CRDL N/A
- Revenue This Year
- IMPP $3.05
- CRDL N/A
- Revenue Next Year
- IMPP $47.92
- CRDL N/A
- P/E Ratio
- IMPP $1.86
- CRDL N/A
- Revenue Growth
- IMPP N/A
- CRDL N/A
- 52 Week Low
- IMPP $2.12
- CRDL $0.77
- 52 Week High
- IMPP $4.59
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- IMPP 63.11
- CRDL 55.91
- Support Level
- IMPP $2.15
- CRDL $0.92
- Resistance Level
- IMPP $2.78
- CRDL $1.08
- Average True Range (ATR)
- IMPP 0.15
- CRDL 0.11
- MACD
- IMPP 0.04
- CRDL 0.02
- Stochastic Oscillator
- IMPP 74.36
- CRDL 93.92
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.